Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/12/2003WO2003017928A3 Method for treating bronchial constriction and bronchospam
06/12/2003WO2003016273A3 Peptide arginals and methods for treating disseminated intravascular coagulation
06/12/2003WO2003005962A3 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate
06/12/2003WO2002078703A8 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
06/12/2003WO2002064094A3 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
06/12/2003WO2002057465A3 Method for producing polyunsaturated fatty acids, novel biosynthesis genes and novel plant expression constructs
06/12/2003WO2002055692A3 Method for inhibiting the expression of a target gene and medicament for treating a tumor disease
06/12/2003WO2002009683A9 Aldosterone blocker therapy to prevent or treat inflammation-related disorders
06/12/2003WO2002000844A3 Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use
06/12/2003WO2001088126A8 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
06/12/2003WO2001085096A9 Mast cell regulation
06/12/2003WO2001073133A9 Compositions and methods for identifying and targeting cancer cells
06/12/2003WO2001071007A3 GENETIC POLYMORPHISM OF MxA PROTEIN AND USE THEREOF
06/12/2003WO2001054677A9 Ace inhibitor-vasopressin antagonist combinations
06/12/2003US20030109813 Energy-activated targeted cancer therapy
06/12/2003US20030109723 Processing method of lactionization in the preparation of statins
06/12/2003US20030109715 3,4-Dihydro-1H-naphthalene derivatives as a highly selective cyclooxygenase-2 inhibitor
06/12/2003US20030109709 Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
06/12/2003US20030109702 Fungicides, bactericides
06/12/2003US20030109701 Crystalline forms of meloxicam and processes for their preparation and interconversion
06/12/2003US20030109700 Antilipemic agents, anticholesterol agents, cardiovascular disorders, antiischemic agents
06/12/2003US20030109699 Biopolymers; gene therapy, medical diagnosis
06/12/2003US20030109688 Purification using cationic ion exchange resins
06/12/2003US20030109671 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/12/2003US20030109639 Formulations of active components in the form of a solid dispersion
06/12/2003US20030109585 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
06/12/2003US20030109584 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
06/12/2003US20030109583 Treating bacterial infections. In one aspect, the invention comprises orally administering a pharmaceutical composition to an animal, wherein the composition comprises a pharmaceutically acceptable excipient and an antibacterial
06/12/2003US20030109582 Methods and compositions for stimulating secretions from paneth cells
06/12/2003US20030109580 Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase - 2
06/12/2003US20030109578 Treating acute and chronical inflammatory processes in a patent in need thereof which comprises administering to such patent an amount effective therefor of a compound or salt thereof according to claim 1.
06/12/2003US20030109577 Pharmaceutical composition containing citalopram
06/12/2003US20030109576 Tartrate salts of (r) -3-n,n- dicyclobutylamino-8-fluoro-3,4-dihydro-2h-1- benzopyran-5-carboxamide
06/12/2003US20030109575 Emulsion of tocopherol incorporating a co-solvent and, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans by
06/12/2003US20030109573 A stent comprised of a stent body coated with a compound of the following formula:with hetero compounds
06/12/2003US20030109572 Wortmannin analogs and methods of using same
06/12/2003US20030109571 Thromboxane ligands without blood clotting side effects
06/12/2003US20030109570 Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases
06/12/2003US20030109568 1H-indole derivatives as a highly selective cyclooxygenase-2 inhibitor
06/12/2003US20030109567 Antitumor agent which comprises said compound or a physiologically acceptable salt thereof as an active ingredient.
06/12/2003US20030109566 Therapeutic treatment of diseases in optic nerve and the like.
06/12/2003US20030109565 Administered by any means other than orally, characterized in that it comprises xylitol, and more particularly to an antipyretic preparation characterized in that it consists of an antipyretic and a synergistic amount of xylitol.
06/12/2003US20030109564 Treating: allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep
06/12/2003US20030109562 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1, 6,9-trioxa-3-aza-cyclopenta[a]naphthalene
06/12/2003US20030109561 Treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser
06/12/2003US20030109558 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
06/12/2003US20030109557 Calcium channel blockers such as amlodipine in the treatment of renal disease in normotensive animals. Also described are new unit doses of amlodipine suitable for the treatment of renal disease in normotensive cats.
06/12/2003US20030109556 Melanocortin receptor ligands
06/12/2003US20030109555 Targeted drug delivery using sulfonamide derivatives
06/12/2003US20030109554 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
06/12/2003US20030109553 Conditions associated with diabetes mellitus and certain complications thereof, in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and a biguanide
06/12/2003US20030109552 Prophylaxis of renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease, and microalbuminuria which method comprises administering insulin
06/12/2003US20030109551 A therapeutic or preventive agent for pulmonary insufficiency, containing as an active ingredient a diaminotrifluoromethylpyridine derivative represented by the formula (I) or its salt: anti-inflammatory agent or an anti-
06/12/2003US20030109550 Substituted indazole compounds for the treatment of inflammation
06/12/2003US20030109549 ORL1-receptor agonist activity, and are useful as analgesics or the like in mammalian subjects.
06/12/2003US20030109548 4-hydroxy-2-alkylquniolines for depleting liquids of iron, and for treating diseases associated with iron overload, toxicity, or iron excess. The 4-hydroxy-2-alkylquniolines can be associated with any material in which it retains its
06/12/2003US20030109546 Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
06/12/2003US20030109545 Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors.
06/12/2003US20030109544 Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
06/12/2003US20030109543 Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
06/12/2003US20030109542 Intermediates and methods of treating a herpesvirus infection, atherosclerosis or restenosis using such compounds or salts.
06/12/2003US20030109541 3-Phenyl-3,7-diazabicyclo[3.3.1] nonane compounds, process for preparing them, pharmaceutical compositions containing them and use thereof to inhibit cardiac arrhythmia
06/12/2003US20030109540 Pharmaceutical dosage forms comprising descarboethoxyloratadine
06/12/2003US20030109539 Treating a condition selected from the group consisting of anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and improved cognition, in a subject in need thereof comprising administering a compound
06/12/2003US20030109538 Pyrmidine derivatives as selective inhibitors of cox-2
06/12/2003US20030109537 Methods and materials for treating bone conditions
06/12/2003US20030109536 Treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. treatment of anxiety, depression, a sleep disorder, attention deficit disorder, or Alzheimer's dementia,
06/12/2003US20030109535 GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:prodrugs, stereoisomers and drugs
06/12/2003US20030109534 Non-peptide CCR1 receptor antagonists for the treatment of progressive renal fibrosis
06/12/2003US20030109533 New benzenesulphonamide compounds
06/12/2003US20030109532 Modulators of dopamine neurotransmission
06/12/2003US20030109530 Diabetes, insulin resistance, dyslipidemia, obesity, high blood pressure, atherosclerosis, retinopathies and neurodegenerative disorders; synthesis by reacting a biguanide with an aldehyde, semiacetal or acetal in presence of acid catalyst
06/12/2003US20030109529 Treating humans and animals infected by Apicomplexan parasites. More specifically, the present invention relates to treating an Apicomplexan infection by administering s-triazines, such as atrazine, to an infected human or animal.
06/12/2003US20030109527 Novel hydroxy diphenylurea sulfonamides, compositions and intermediates thereof. The hydroxy
06/12/2003US20030109526 Azo amino acids derivatives
06/12/2003US20030109525 Provides crystals including a thiazine oxazolidinone. Thiazine oxazolidinones are useful as antimicrobials including gram-positive aerobic bacteria such as multiply-resistant staphylococci and streptococci, gram-negative aerobic
06/12/2003US20030109524 Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists
06/12/2003US20030109523 Bicyclic antagonists selective for the alphavbeta3 integrin
06/12/2003US20030109522 Ophthalmologic treatment methods using selective iNOS inhibitors
06/12/2003US20030109521 Aryl substituted thiazolidinones and the use thereof
06/12/2003US20030109520 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
06/12/2003US20030109519 Use of selective potassium channel openers
06/12/2003US20030109518 Substituted 1,4-benzodiazepines and uses thereof
06/12/2003US20030109517 Azacycloalkanone serine protease inhibitors
06/12/2003US20030109516 Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof
06/12/2003US20030109515 Pharmaceutical formulation of a platinum derivative
06/12/2003US20030109514 Platinum derivative pharmaceutical formulations
06/12/2003US20030109513 B-ring estratrienes
06/12/2003US20030109512 Use of 4-androstenediol and 4-androstenediol in a transdermal formulation to increase testosterone levels in humans
06/12/2003US20030109511 Novel anti-inflammatory androstane derivative compositions
06/12/2003US20030109510 Pharmaceutical formulations comprising a combination of (R,R)-formoterol and budesonide and the use of such formulations in medicine, particularly in the prophylaxis and treatment of respiratory diseases
06/12/2003US20030109509 Methods for treating dry eye
06/12/2003US20030109508 Administering fixed combinations of MUC-1 secretagogues, such as HETE derivatives, and androgen compounds are disclosed.
06/12/2003US20030109507 Relates to semisolid transcutaneous medicaments based on at least one oxidation-sensitive progestin or a pharmaceutically acceptable derivative thereof. The medicaments comprise ascorbic acid, an ascorbic acid derivative or a salt thereof
06/12/2003US20030109506 Treating vitamin D responsive diseases
06/12/2003US20030109505 Medicament for the treatment of diseases caused by parasitic protozoa
06/12/2003US20030109504 Inhibit metabotropic glutamate receptor activity, or activation, for use in the treatment of movement disorders associated with a poverty of movement (e.g. Parkinson's disease). The compounds are particularly useful when used in
06/12/2003US20030109503 Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
06/12/2003US20030109502 Novel compounds for modulating cell proliferation
06/12/2003US20030109501 High throughput assay for N-sulfotransferase activity of glucosaminyl N-deacetylase/N-sulfotransferases
1 ... 5438 5439 5440 5441 5442 5443 5444 5445 5446 5447 5448 5449 5450 5451 5452 5453 5454 5455 5456 5457 5458 ... 7860